Egalet Corp (EGLT) 11.75 $EGLT
Egalet to Host Conference Call and Webcast to Discuss First Quarter 2014 Financial Results on May 13, 2014
PR Newswire - Tue Apr 29, 7:00AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
today announced that its first quarter financial results will be released on Tuesday, May 13, 2014. Following the announcement, Egalet's management will host a live conference call and webcast at 8:30 a.m. Eastern Time to review the company's financial and operating results and provide a general business update.
Egalet Corporation [EGLT] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Wed Apr 23, 9:22AM CDT
What:
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 22, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Egalet to Present at the 13th Annual Needham Healthcare Conference on April 9
GlobeNewswire - Wed Apr 02, 8:43AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet" today announced that Bob Radie, president and chief executive officer, is scheduled to present next week at the 13 Annual Needham Healthcare Conference on Wednesday, April 9, 2014, at 2:20 p.m. EDT. The conference will be held at the Westin NY Grand Central Hotel.
Egalet Added to Russell 3000, Russell 2000 and Russell Global Indexes
GlobeNewswire - Tue Apr 01, 8:25AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet", a specialty pharmaceutical company developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and other indications, announced today that it was added to the Russell 3000(R), Russell 2000(R) and Russell Global Indexes as part of Russell Investments' first quarter IPO additions. The change to the indexes took effect at the close of the U.S. markets yesterday Monday, March 31, 2014.
Egalet Reports Positive Outcome of First Phase of Category 1 Abuse Deterrence Studies for Egalet-001
GlobeNewswire - Mon Mar 31, 7:15AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet" today announced positive results of the first phase of the category 1 abuse deterrence studies for Egalet-001, an abuse-deterrent, extended-release, oral morphine product in development for the treatment of moderate to severe chronic pain. The product uses Egalet's proprietary technology which is specifically designed to deter abuse by physical and chemical manipulation while also providing the ability to tailor the release of the active pharmaceutical ingredient (API).
Egalet Reports Full Year 2013 Financial Results and Provides Business Update
PR Newswire - Wed Mar 26, 6:00AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet" today reported business highlights and financial results for the year ended December 31, 2013. This marks the first time that Egalet is reporting its operating results as a public company.
Egalet Initiates Bioequivalence Studies for Abuse-Deterrent Morphine Egalet-001
GlobeNewswire - Tue Mar 25, 7:00AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet" today announced the initiation of the bioequivalence (BE) program for Egalet-001, an abuse-deterrent, extended-release, oral morphine product in development for the treatment of moderate to severe chronic pain. These studies are intended to establish bioequivalence of Egalet-001 to MS Contin(R) (morphine sulfate controlled-release) ("MS Contin".
Egalet to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2013 Financial Results on March 26, 2014
PR Newswire - Thu Mar 13, 7:00AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet" today announced that its fourth quarter and year ended December 31, 2013 financial results will be released on Wednesday, March 26, 2014. Following the announcement, Egalet's management will host a live conference call and webcast at 8:30 a.m. Eastern Time to review the company's financial and operating results and provide a general business update.
Egalet Appoints Timothy P. Walbert to Board of Directors
GlobeNewswire - Tue Mar 11, 7:14AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet" today announced the appointment of Timothy P. Walbert, chairman, president and chief executive officer of Horizon Pharma, to its board of directors.
Why Egalet Corp. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 10, 12:37PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Egalet , a clinical-stage specialty...
Egalet IPO Underwriters Exercise Over-Allotment Option
GlobeNewswire - Mon Mar 10, 7:00AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet" today announced that the underwriters of its initial public offering (IPO) have exercised their option to purchase 630,000 shares of common stock at the IPO price of $12.00 per share to cover over-allotments. The sale of these additional shares of common stock closed earlier today. Egalet estimates net proceeds from the offering to be approximately $7.5 million, after deducting underwriting discounts and commissions.
Egalet to Host Conference Call and Webcast to Discuss First Quarter 2014 Financial Results on May 13, 2014
PR Newswire - Tue Apr 29, 7:00AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
today announced that its first quarter financial results will be released on Tuesday, May 13, 2014. Following the announcement, Egalet's management will host a live conference call and webcast at 8:30 a.m. Eastern Time to review the company's financial and operating results and provide a general business update. Egalet Corporation [EGLT] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Wed Apr 23, 9:22AM CDT
What:
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 22, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Egalet to Present at the 13th Annual Needham Healthcare Conference on April 9
GlobeNewswire - Wed Apr 02, 8:43AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
today announced that Bob Radie, president and chief executive officer, is scheduled to present next week at the 13 Annual Needham Healthcare Conference on Wednesday, April 9, 2014, at 2:20 p.m. EDT. The conference will be held at the Westin NY Grand Central Hotel. Egalet Added to Russell 3000, Russell 2000 and Russell Global Indexes
GlobeNewswire - Tue Apr 01, 8:25AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
, a specialty pharmaceutical company developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and other indications, announced today that it was added to the Russell 3000(R), Russell 2000(R) and Russell Global Indexes as part of Russell Investments' first quarter IPO additions. The change to the indexes took effect at the close of the U.S. markets yesterday Monday, March 31, 2014. Egalet Reports Positive Outcome of First Phase of Category 1 Abuse Deterrence Studies for Egalet-001
GlobeNewswire - Mon Mar 31, 7:15AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
today announced positive results of the first phase of the category 1 abuse deterrence studies for Egalet-001, an abuse-deterrent, extended-release, oral morphine product in development for the treatment of moderate to severe chronic pain. The product uses Egalet's proprietary technology which is specifically designed to deter abuse by physical and chemical manipulation while also providing the ability to tailor the release of the active pharmaceutical ingredient (API). Egalet Reports Full Year 2013 Financial Results and Provides Business Update
PR Newswire - Wed Mar 26, 6:00AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
today reported business highlights and financial results for the year ended December 31, 2013. This marks the first time that Egalet is reporting its operating results as a public company. Egalet Initiates Bioequivalence Studies for Abuse-Deterrent Morphine Egalet-001
GlobeNewswire - Tue Mar 25, 7:00AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
today announced the initiation of the bioequivalence (BE) program for Egalet-001, an abuse-deterrent, extended-release, oral morphine product in development for the treatment of moderate to severe chronic pain. These studies are intended to establish bioequivalence of Egalet-001 to MS Contin(R) (morphine sulfate controlled-release) ("MS Contin". Egalet to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2013 Financial Results on March 26, 2014
PR Newswire - Thu Mar 13, 7:00AM CDT
Egalet Corporation (Nasdaq: EGLT) ("Egalet"
today announced that its fourth quarter and year ended December 31, 2013 financial results will be released on Wednesday, March 26, 2014. Following the announcement, Egalet's management will host a live conference call and webcast at 8:30 a.m. Eastern Time to review the company's financial and operating results and provide a general business update. Egalet Appoints Timothy P. Walbert to Board of Directors
GlobeNewswire - Tue Mar 11, 7:14AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
today announced the appointment of Timothy P. Walbert, chairman, president and chief executive officer of Horizon Pharma, to its board of directors. Why Egalet Corp. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 10, 12:37PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Egalet , a clinical-stage specialty...
Egalet IPO Underwriters Exercise Over-Allotment Option
GlobeNewswire - Mon Mar 10, 7:00AM CDT
Egalet Corporation (Nasdaq:EGLT) ("Egalet"
today announced that the underwriters of its initial public offering (IPO) have exercised their option to purchase 630,000 shares of common stock at the IPO price of $12.00 per share to cover over-allotments. The sale of these additional shares of common stock closed earlier today. Egalet estimates net proceeds from the offering to be approximately $7.5 million, after deducting underwriting discounts and commissions. 
